Login / Signup

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study.

Maya H BuchDeepak L BhattChristina Charles-SchoemanJon T GilesTed MikulsGary G KochSteven YtterbergEdward NagyHyejin JoKenneth KwokCarol A ConnellKarim Richard MasriArne Yndestad
Published in: RMD open (2024)
NCT02092467.
Keyphrases
  • rheumatoid arthritis
  • clinical trial
  • open label
  • double blind
  • study protocol
  • placebo controlled
  • electronic health record